Dr. Fox Remains a Shareholder and Member of the Board of Directors; Board Members Dr. David McFarland & Dr. Lorraine ...

Physical therapy isn't only for athletes. Anyone who needs help meeting movement goals and regaining independence can benefit ...

Recommendations for RehabilitationWhen you hear the word "rehabilitation," what comes to mind?If you have spondyloarthritis, ...

When Celia was looking for a physical therapist who made home visits, she posted on the Teaneck shuls email list that she ...

Juvmo was designed to offer a reduction in motor symptoms, while reducing non-motor side effects, through its more selective ...

Tavapadon, a treatment for Parkinson’s disease recently approved by the FDA, provides a novel option for healthcare providers ...

On Monday, Sept. 28, the U.S. Food and Drug Administration approved a new treatment that targets dopamine pathways critical ...

Tavapadon (Juvmo) is the first selective D1/D5 dopamine receptor agonist approved for adult Parkinson disease, positioning a mechanistically differentiated oral, once-daily dopaminergic strategy.

The FDA has approved tavapadon (AbbVie), a once-daily oral selective dopamine D1/D5 receptor partial agonist, for adults with ...

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of ...

Juvmo (tavapadon) offers a novel, selective D1/D5 dopamine receptor partial agonist mechanism for early monotherapy and adjunctive treatment in Parkinson disease.

ST. LOUIS — Tim Ezell says a frequency therapy treatment has improved his balance and movement as he continues living with Parkinson's disease. Ezell has been receiving treatment five days a week at ...